Two Madison life sciences companies recently announced they had received funding from investors, according to filings with the U.S. Securities and Exchange Commission.

FluGen Inc., a Madison-based firm developing a universal flu vaccine, raised $5.58 million in funding through 36 investors, according to the filing. FluGen, which already has investments from Madison’s Venture Investors, the state’s largest venture capital fund, recently shared data from its first test on humans at the annual ID Week conference in San Francisco.

Since 2011, the company has raised roughly $30 million.

Meanwhile, Imbed Biosciences Inc., a Fitchburg-based company that makes medical devices for wound care, reported raising $1.05 million through 14 investors. The money raised is part of an overall goal of $3.5 million.

Imbed Biosciences launched its product, MicroLyte Ag Matrix, an ultra thin, synthetic sheet that kills bacteria upon contact, earlier this year.

Messages left for both companies were not returned. Read the full story here.